Adrian Newman-Tancredi, PhD, DSc, has over 25 years of experience in pharma industry neuroscience research and drug discovery. Prior to joining Neurolixis, he was director of neurobiology at Pierre Fabre, where he led multi-disciplinary programs that successfully identified novel central nervous system (CNS) drugs. Prior to Pierre Fabre, Dr. Newman-Tancredi led a molecular pharmacology team at Servier, where he investigated signal transduction mechanisms of monoamine receptors. Drugs characterized in the course of Dr. Newman-Tancredi's work include milnacipran (Savella), piribedil (Trivastal), agomelatine (Valdoxan), levomilnacipran (Fetzima) and the serotonergic ‘biased agonist,’ NLX-101.

Dr. Newman-Tancredi leads the development program on NLX-112 (befiradol), a drug candidate for treatment of levodopa-induced dyskinesia. Dr. Newman-Tancredi has published over 170 research reports, co-authored patents on new chemical entities (NCEs) and given presentations to a wide variety of audiences. He received his BSc with honors in biochemistry, followed by a PhD and a DSc in neuropharmacology, from the University of Kent at Canterbury, United Kingdom.